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Abstract
The diversity in the Plasmodium falciparum genome can be used to explore parasite population dynamics, with practical
applications to malaria control. The ability to identify the geographic origin and trace the migratory patterns of parasites
with clinically important phenotypes such as drug resistance is particularly relevant. With increasing single-nucleotide
polymorphism (SNP) discovery from ongoing Plasmodium genome sequencing projects, a demand for high SNP and sample
throughput genotyping platforms for large-scale population genetic studies is required. Low parasitaemias and multiple
clone infections present a number of challenges to genotyping P. falciparum. We addressed some of these issues using a
custom 384-SNP Illumina GoldenGate assay on P. falciparum DNA from laboratory clones (long-term cultured adapted
parasite clones), short-term cultured parasite isolates and clinical (non-cultured isolates) samples from East and West Africa,
Southeast Asia and Oceania. Eighty percent of the SNPs (n = 306) produced reliable genotype calls on samples containing as
little as 2 ng of total genomic DNA and on whole genome amplified DNA. Analysis of artificial mixtures of laboratory clones
demonstrated high genotype calling specificity and moderate sensitivity to call minor frequency alleles. Clear resolution of
geographically distinct populations was demonstrated using Principal Components Analysis (PCA), and global patterns of
population genetic diversity were consistent with previous reports. These results validate the utility of the platform in
performing population genetic studies of P. falciparum.
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Introduction
Plasmodium falciparum continues to impose a substantial public
health burden across the globe, causing an estimated 500 million
clinical cases and 1–2 million deaths each year [1]. The lack of an
effective antimalarial vaccine and the emergence and spread of
parasite resistance to affordable antimalarial drugs such as
chloroquine and sulfadoxine-pyrimethamine, have greatly con-
tributed to the public health burden of malaria [2]. More
worryingly, reports are appearing of evolving resistance to
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20251
artemisinin combination therapies, currently the frontline treat-
ment throughout the world. [3]. Effective measures to control
malaria and reduce parasite transmission in the face of drug
resistance are urgently needed.
Subsets of genetic polymorphisms can be used to explore the
dynamics of parasites with important phenotypes such as drug
resistance, with practical applications to malaria control and
elimination. Key to the success of malaria control strategies is an
understanding of the parasite genetic diversity and dynamics/
exchange of gene flow between human populations. With this
knowledge, effective spatial and temporal boundaries for inter-
vention can be implemented. The ability to identify the geographic
origin and monitor the migration patterns of clinically important
parasite genetic traits should greatly facilitate control efforts, with
important applications for drug resistance surveillance. With
sufficient genetic information, we may be able to use the spectrum
of genetic variation, or in a more simplified form, a ‘‘molecular
barcode’’, to elucidate the geographic origin of an infection.
Molecular barcodes have already been used successfully by
Daniels and colleagues [4] to distinguish parasite clones from
one another.
With ongoing whole-genome Plasmodium sequencing efforts
providing a valuable resource of SNPs (http://www.sanger.ac.uk/
research/projects/malariaprogramme-kwiatkowski/), and enhanc-
ing the feasibility of large scale genotype-based population genetic
studies of the parasite, a demand for effective high sample and SNP
throughput genotyping platforms is anticipated. However, geno-
typing P. falciparum samples presents a number of challenges
including limited DNA quantity, an abundance of contaminating
human DNA, extensive polymorphism that may occur in primer
binding sites, and multiple clone infections in which multiple
parasite clones may be present at any number and ratio.
To address some of these limitations, we developed a
customized Illumina GoldenGate 384-SNP genotyping assay.
The GoldenGate platform was chosen for the study owing to the
moderately high sample (96 samples in parallel) and SNP (up to
1536 loci) throughput, and the custom design feature, which
enables users to tailor the SNP genotyping assay to meet the
specific requirements of their study. Using P. falciparum clones and
isolates from East and West Africa, Southeast Asia and Oceania,
we measured the specificity and sensitivity of the GoldenGate
platform on various preparations of P. falciparum DNA. In addition,
we characterise the genetic structure of parasite populations and
assess the potential of molecular barcoding approaches to identify
the likely geographic origin of an infection.
Materials and Methods
Parasite samples and DNA preparation
P falciparum DNA was obtained from either i) long-term cultured
parasite clones (laboratory parasite 3D7, HB3 and IT), ii) short-
term culture parasite isolates obtained from patients with malaria
(in Kenya, Cambodia and Thailand), and (iii) non-cultured
parasite isolates obtained directly from patient’s blood (malaria
clinical samples collected in Mali, Burkina Faso and Papua New
Guinea (PNG) (Table S1). Laboratory clones and short-term
parasite cultures were grown in vitro as previously described [5]. All
samples were collected with written informed consent from adult
patient or a parent or guardian of paediatric patients. The projects
were approved by all the relevant ethical committees (Comite
d’Ethique de la Faculte´ de Me´decine de Pharmacie et d’Odontos-
tomatologie, Bamako, Mali, Comite d’Ethique Institutionnel du
Centre Muraz, Bobo- Dioulasso, Burkina Faso, Institutional
Review Board (IRB) of National Institute of Allergy and Infectious
Diseases, United States, Cambodian National Ethics Committee
for Health Research, IMR Institutional Review Board, Madanga,
Medical Research Advisory Committee of Papua-New-Guinea,
Ethics Committee of the Faculty of Tropical Medicine at Mahidol
University , Bangkok, Thailand, KEMRI scientific, ethical and
export license approval, Oxford Tropical Research Ethical
Committee (OxTREC) ethical approval and Heidelberg ethical
approval for Kenyan samples).
Prior to DNA extraction, all blood samples were subject to
white blood cell depletion to reduce human DNA contamination
using a combination of lymphoprep density gradient centrifuga-
tion (Axis-Shield) followed by Plasmodipur filtration (Euro-
Diagnostica), as described in (Auburn et al., submitted). Genomic
DNA was extracted from infected red blood cell pellets using the
QIAamp DNA Blood Midi Kit according to the manufacturer’s
protocol (QIAGEN). Whole genome amplification was undertaken
on DNA template (5–10 ng of total DNA) using Genomiphi’s
Multiple Displacement Amplification kit as per protocol (Amer-
sham Biosciences). Human DNA extracted from an EBV-
transformed B cell line obtained from the Centre d’Etude du
Polymorphisme Humain collection (Coriell Institute for Medical
Research) was used as a control and in preparations of human-
spiked Plasmodium samples for the assessment of the effect of
human DNA presence on Plasmodium genotyping efficacy. To
address the quantities of human and Plasmodium DNA in each
sample, quantitative real time PCR (QRT-PCR) analysis using
human and parasite-specific primers was undertaken using the
Applied Biosystems StepOne RT-PCR system (Auburn et al.,
submitted).
SNP selection and genotyping
An Illumina 384-SNP custom GoldenGate assay was used to
genotype P. falciparum samples. SNPs were identified in PlasmoDB
version 4.4 (www.plasmoDB.org) [6] using the following criteria:
(a) polymorphic between 3 P. falciparum laboratory clones (3D7,
possible African origin, HB3 from Honduras, IT from Brasil) with
at least 1 observation of each allele, (b) Illumina assay design score
.1 (scores are determined by the Illumina Assay Design Tool and
minimum recommendations are based on Illumina internal
testing) (c) uniform spacing across the P.falciparum genome. The
final set of 384 SNPs consisted of 31 well-known candidate gene
SNPs and 353 SNPs chosen to achieve on average 1 marker per
60 kb (Table S2). The reference sequence genome of the 3D7
parasite clone [7] was used for assay design. Genotyping was
performed using the manufactures protocol on 96-well format
Sentrix arrays [8]. This system uses a high-density BeadArray
technology in combination with an allele-specific extension,
adapter ligation and amplification assay protocol. Briefly,
biotinylated DNA was immobilized on paramagnetic beads and
the pooled SNP-specific oligonucleotides were annealed on the
DNA. Oligonucleotides that hybridized were then extended and
ligated to generate DNA templates which were amplified using
universal fluorescently-labelled primers. Single-stranded PCR
products were hybridized to a SentrixH Array Matrix. Arrays
were imaged using a BeadArray Reader Scanner. All samples were
genotyped at least in duplicate in the same array/plate. A number
of samples were repeated in different plates. Laboratory clones
were genotyped using a range of DNA quantities (0.25–250 ng of
total DNA). A minimum of 2–5 ng of total DNA was used to
genotype the remaining samples.
Assay performance
Illumina’s Bead Studio software converts allele intensities for
each SNP into polar coordinate-based variables to call genotypes:
Population Genetic Analysis of P. falciparum
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allelic intensity ratios (theta) that range from 0 to 1 and intensity
values (R) with values from 0 onwards. Theta values approximat-
ing 0 and 1 reflect different alleles and, thus, theta is used to score
genotypes as heterozygous or homozygous for each allele [9]. R
values represent overall SNP intensity, whereby values ,0.1 are
considered poor intensity [9]. The genotype calling strategy was
based on the distribution of theta values in pure and artificial
mixes of laboratory clones, where the expected genotype call is
known (see Figure 1). Correlations between the theta values were
estimated to assess the degree of concordance between replicates
(Pearson’s correlation coefficient). Additionally, genotype concor-
dance was assessed by comparing genotype calls and by comparing
replicate standard deviations (concordance of theta values was
considered for standard deviation ,0.05). SNPs with R,0.1 and/
or no correlation between replicates were considered failures and
removed from further analysis.
Population genetic analysis
Expected heterozygosity (HE) at each locus was calculated as
HE=n/(n-1)](2pq), where n is the number of infections sampled, p
is the frequency of allele 1 and q is the frequency of allele 2. The
formula [n/(n-1)] was included to enable adjustment for sample
size. At the population level, HE was averaged across all loci [10].
Principal component analysis (PCA) was performed by
calculating the eigenvalues and their vectors (PCs) of a matrix
consisting of average number of pairwise genotype or theta
differences between each isolate. The proportion of total variation
explained by each principal component was estimated using
eigenvalues. The genetic differentiation between populations was
assessed using pair-wise measures of Wright’s Fixation index (FST),
using both theta values and genotype calls [11]. Calculations were
only undertaken where the sample size of both populations was
.15. Sets of informative SNPs for assessment of population
divergence were constructed by ranking FST statistics (Cockerham
and Weir) [10] calculated at each SNP position.
Results
Assay performance on laboratory clones: 3D7, HB3, IT
Validation of the 384-SNP assay was undertaken using genomic
DNA from the 3D7 parasite that was used for assay design. A set
of reliable SNPs was identified using the following criteria: (a)
allelic concordance with the reference sequence [7], (b) genotype
intensity (R.0.1), (c) genotype concordance between replicates,
and d) homozygote genotype status (under the assumption of 3D7
clonality). As a result, 319 reliable SNPs (83.1% of total) were
selected for subsequent analyses (Table S2). A high degree of
correlation (r2.0.99) was observed for both inter- and intra-plate
replicates for this set of SNPs, demonstrating overall low
experimental variability on the GoldenGate platform (Table 1).
The performance of the platform was further tested across the
reliable SNPs using DNA from HB3 and IT laboratory clones.
More than 95% of the 319 loci analysed performed well, as
demonstrated by the genotype intensity signals and genotype
Figure 1. Distribution of theta values (proxy to genotype call) at 319 ‘‘reliable’’ SNPs in preparations from the laboratory clones
3D7 and HB3, and in artificial mixtures of the two clones. Mixing proportions of the clones (HB3:3D7) are indicated in brackets. Red dots
represent the SNPs that should have heterozygous genotypes in the artificial mixes (according to the genotypes from the haploid pure samples),
black dots represent the SNPs for which both samples have the same genotype. Theta values approximating 0.5 correspond to having both alleles
approximating 50% frequency. Values approximating 0 and 1 correspond to homozygous calls for allele a or b. In the pure clonal 3D7 and HB3
samples, the majority of genotype calls exhibit theta values ,0.1 and .0.9.
doi:10.1371/journal.pone.0020251.g001
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concordance between replicates (Table 1). Approximately 25% of
these SNPs were monomorphic between the 3 laboratory clones
(Table S2).
Genotyping efficacy with varying DNA quantity and
preparation
The ability of the assay to perform at lower DNA quantities
than recommended by Illumina (total of 250 ng of DNA) was
investigated by assessing the intensity and genotype concordance
between 250 ng, 25 ng, 2.5 ng and 0.25 ng templates of the clones
3D7, HB3 and IT. For all three parasite clones, the performance
of the 25 ng and 2.5 ng templates was similar to the 250 ng
template (Table 1). Although genotype concordance was lower at
0.25 ng, the overall concordance rate was still moderately high
(97.8%, 77.9% and 95.7% of SNPs for 3D7, HB3 and IT,
respectively).
The influence of human DNA on P. falciparum genotyping
accuracy was also assessed by comparison of the genotype calls
between samples containing only parasite DNA with samples
containing a mixture of parasite and human DNA at different
concentrations (Table S3). Genotype calls were consistent between
the samples containing only parasite DNA and the mixed samples
containing only 0.01% or more of parasite DNA (genotype
correlation: r2.0.96).
Genotyping efficacy was also assessed on P. falciparum samples
subject to whole genome amplification (WGA) using the multiple
displacement amplification (MDA) method [12,13]. WGA prod-
ucts were tested on templates from 3D7, mixtures of 3D7 and
human DNA (1:1 ratio), and two clinical Malian samples (non-
cultured) (Table S4). QRT-PCR on the pre- and post-amplifica-
tion products confirmed that the human DNA had not impeded
amplification of the parasite DNA during the MDA process. More
than 99.4% of the 319 reliable SNPs passed the inclusion criteria
on both the pure 3D7 and in the human:3D7 mixtures.
Furthermore, ,100% genotype call concordance was observed
both between replicates and between the pure 3D7 and the
human:3D7 mixtures. Reliable and reproducible results were also
obtained in comparisons of genomic DNA with the WGA samples
prepared from the two Malian clinical isolates (Table S4).
Genotyping efficacy on clinical and short-term cultured
samples
Given that SNP selection and primer design were based on the
SNP information available in PlasmoDB version 4.4, it is possible
that unidentified SNPs might reduce the genotyping efficacy at a
number of loci, particularly in sample populations that were not
well represented in this version of the database. The genotyping
efficacy at the 319 reliable SNPs was assessed in 143 short-term or
clinical (non-cultured) samples sourced from Burkina Faso, Mali,
Kenya, Cambodia, Thailand and Papua New Guinea. As
summarized in Table 2, on average, 95.5% of the SNPs performed
well across all samples. Thirteen SNPs exhibited low intensity calls
(R,0.1) in more than 80% of samples and were excluded from
further analysis on this sample set, leaving a set of 306 ‘‘globally
reliable SNPs’’ (Table S2). The minor allele frequency (MAF) for
each SNP is presented in Table S2. On this set of 143 samples, 267
SNPs displayed a MAF $5%.
Clinical malaria samples obtained directly from patient’s blood
may have multiple genetically distinct P. falciparum clones. The
presence of heterozygous genotypes is indicative of the presence of
more than one clone (haploid genome) in a single infection
(multiclonality). Examples of the genotype profiles (as theta scores)
of 2 clinical samples (non-cultured) described in this study are
presented in Figure S1. In general, the clinical samples from Africa
exhibited a greater number of heterozygous calls than the clinical
samples from PNG. This observation complies with the results
from a large-scale whole genome sequencing dataset (Manske et al.,
under review). Whole genome sequence data generated on the
Illumina Genome Analyzer platform was available for 105 of the
samples described in this study. Thus, it was possible to assess the
reliability of the GoldenGate genotype calls, by comparison with
the Genome Analyzer calls at 106 of the globally reliable SNPs. .
The full set of globally reliable SNPs could not be compared owing
to regions of low sequence coverage. At the 106 loci, an average
Table 1. Assessment of assay performance using laboratory clones 3D7, IT and HB3.
Sample Genomic DNA (ng) n6 SNPs analyseda Intensity (R.0.1) Filtration A
b Filtration Bc Correlation between replicatesd
n6 SNPs n6 SNPs n6 SNPs
3D7 250 384 343 339 319 1.000
25 319 319 319 319 1.000
2.5 319 319 319 317 0.999
0.25 319 318 313 312 0.999
HB3 250 319 305 315 304 0.999
25 319 303 305 301 0.998
2.5 319 303 302 300 0.999
0.25 319 305 244 237 0.998
IT 250 319 305 307 303 0.999
25 319 305 311 304 0.999
2.5 319 304 306 300 0.995
0.25 319 307 294 290 0.999
a319 SNP set was defined from assessments of genotype concordance in 250 ng replicates of the 3D7 reference strain.
bFiltration criteria A: SNPs with genotype concordance between replicates .0.95.
cFiltration criteria B: SNPs with R.0.1 and with genotype concordance between replicates .0.95.
dMean correlation between replicates.
doi:10.1371/journal.pone.0020251.t001
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genotype concordance of 97.8% (including both homozygous and
heterozygous genotypes) was observed between the two datasets
(Manske et al., under review).
Genotype calling sensitivity in mixtures of laboratory
clones
In contrast to clonal laboratory parasites [14], clinical malaria
infections may carry multiple clones present in any number and at
any ratio. In order to assess the sensitivity of the GoldenGate
platform to detect the presence of multiple clones (i.e. minor
alleles), mixtures of DNA from the laboratory clones 3D7 and
HB3 were prepared at known ratios (1:1, 1:2, 1:4, 1:10, 1:20, 1:50,
and 1:100). Figure 1 presents a selection of plots illustrating the
genotype profiles (theta values) for the pure clones and for the
mixtures. In the pure HB3 and 3D7 samples, the large majority of
SNPs (.99%) exhibit theta scores ,0.1 and .0.9 (homozygous
genotypes, as clones are haploid). Thus, a theta value between 0.1–
0.9 was employed for assignment of heterozygous status (in this
case, indicating the presence of more than one haploid clone). As
the genotype calls for each individual clone were known, it was
possible to determine which loci should exhibit heterozygous
genotypes in the mixtures. At ratios of 1:1, only 5 SNPs expected
to exhibit heterozygous genotypes could not be distinguished from
homozygous loci. All other expected heterozygous loci were clearly
distinguishable from the homozygous loci, and exhibited theta
values between 0.1–0.9. At ratios of 1:2 and 1:4, it was still possible
to discriminate 84.7% and 71.5% of the expected heterozygous
SNPs (theta between 0.1–0.9). At ratios of 1:10, discrimination had
decreased to 34.7%. At lower ratios, the assay clearly tended
toward the genotype calls of the predominant parasite and it was
not possible to discriminate different clones within the mixture.
Population genetics: population diversity, differentiation
and geographic positioning
Using the data from the 143 clinical and short-term cultured
samples at the 306 globally reliable SNPs (Table S2), we assessed
several population genetic parameters including the genetic
diversity within each population, inter-population differentiation,
and the ability to assign geographic origins to samples on the basis
of their Principal Component Analysis (PCA) clustering pattern.
Analysis was performed using both homozygous and heterozygous
calls. In general, the large majority of loci displayed homozygous
calls. On average, ,0.6% of the calls in the samples from PNG
and ,8% of the calls in the samples from Africa were
heterozygous. Indeed, where heterozygous calls were observed,
as illustrated in Figure S1, the majority of these displayed a theta
score close to 0 or 1, indicative of a predominant allele. This minor
allele frequency spectrum has also been observed in Illumina
Genome Analyzer sequence data generated on clinical samples
from Africa (Manske et al., under review).
The level of genetic diversity in each population was assessed
using a measure of the expected heterozygosity with adjustment
for sample size (Table 3). Global patterns of P. falciparum diversity
were consistent with previous reports [15,16,17,18], with higher
levels of diversity in the three African populations, Kenya, Mali
and Burkina Faso (HE=0.23, 0.24, and 0.24, respectively), than in
the Thailand, Cambodia and Papua New Guinea samples
(HE=0.17, 0.18, and 0.18, respectively). This would fit with the
view that P. falciparum originated in Africa, and that some of the
ancestral diversity has been lost as it has spread to other parts of
the world; an alternative explanation might be that the level of
diversity is related to historical levels of transmission intensity,
which have tended to be higher in Africa than in Southeast Asia.
Pair-wise estimates of the differentiation between the parasite
populations were calculated using Wright’s Fixation index (FST)
[11]. A summary of these results is presented in Table 3. Low
levels of differentiation were observed within continental bound-
aries (all FST,0.1), particularly between Mali and Burkina Faso
(FST,0.011). High levels of differentiation were observed between
Papua New Guinea and all other populations, with a trend of
increasing differentiation by distance (PNG FST comparisons:
Cambodia = 0.243, Thailand= 0.253, Kenya= 0.275, Burkina
Faso = 0.389, and Mali = 0.391). A similar trend of increasing
differentiation by distance was observed between the Asian and
African populations. High levels of differentiation were observed
between Kenya and each of Cambodia (FST= 0.326) and Thai-
land (FST = 0.329), but the highest levels of differentiation were
observed between the Asian and West African populations (FST
range 0.454–0.463). As with the heterozygosity patterns, these
global patterns of population differentiation are consistent with
previous reports for P. falciparum [19,20].
Principal Components Analysis (PCA) was used to assess the
ability to assign the geographic origin of a given sample on the
basis of its clustering pattern and underlying molecular barcode
(Figure 2). Using the 306 globally reliable SNPs, distinct clustering
of continental populations was observed (Africa, Southeast Asia
and Oceania), with moderate distinction of intra-continental
Table 2. Assessment of assay performance using P. falciparum samples obtained from patients with malaria (short-term and non-
cultured samples).
Intensity (R.0.1) Filtration Aa Filtration Bb Correlation between replicatesc
Origin No. samples n6 SNPs n6 SNPs n6 SNPs
PNG 23 310 312 309 0.997
Thailand 19 313 311 306 0.998
Cambodia 22 299 310 295 0.996
Kenya 19 310 305 304 0.998
Burkina Faso 37 308 314 307 0.999
Mali 23 311 313 307 0.999
Samples assessed on 319 ‘‘reliable’’ SNPs.
aFiltration criteria A: SNPs with genotype concordance between replicates .0.95.
bFiltration criteria B: SNPs with R.0.1 and with genotype concordance between replicates .0.95.
cMean correlation between replicates.
doi:10.1371/journal.pone.0020251.t002
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geographic boundaries (Thailand versus Cambodia, and West
Africa versus East Africa). Despite the political assignment of Mali
and Burkina Faso as separate populations, levels of gene flow
between these populations appeared to be high, with no distinct
clustering. Thus, it was not possible to unambiguously assign
samples to either country. By calculating the FST statistics [10] at
each SNP for different pair-wise population comparisons, it was
possible to rank the polymorphisms by their ability to differentiate
populations. Several alleles have reached fixation (or very high
allele frequencies) in certain populations enabling the identifica-
tion of a set of SNPs that can effectively discriminate samples from
different geographic locations, for example, between continents or
countries. In doing so, it was possible to ascertain a minimum
number of informative SNPs (i.e., molecular barcode) that would
clearly differentiate sample populations. Using this approach, a 9-
SNP molecular barcode was identified which could resolve
samples at the continental level, a 6-SNP barcode with modest
resolution of Thai and Cambodian samples, and a 4-SNP barcode
with modest resolution of East and West African samples (Figure
S2 and Table S2). Using a 13-SNP barcode, low resolution of Mali
and Burkina Faso was possible, but more informative markers are
required to improve this resolution (increasing the number of
SNPs did not improve separation). As the informative SNPs were
selected on the basis of allele frequencies at or close to fixation
within a population, low levels of heterozygous calls are generally
observed within populations at these SNP loci. Indeed, the
informative SNP data sets did not change when excluding data
with heterozygous genotyping calls. The sets of informative SNPs
are expected to change with further information from larger
sample sets from broader geographic regions. Ongoing whole
genome sequencing projects should facilitate identification of more
informative markers for high-resolution molecular barcodes.
Discussion
To successfully implement and monitor malaria control and
elimination strategies, we need a greater understanding of the
dynamics of parasite gene flow between populations and effective
and rapid tools for tracing important parasite genetic traits such as
anti-malarial drug resistance. Microsatellite-based approaches are
common-place for elucidating the population genetic structure of
parasite populations [19,20], and various methods including msp
typing [21] and a 24-SNP TaqMan assay [4] have been described
for genetically distinguish P. falciparum parasites.
Rapidly accumulating genome-wide P. falciparum SNP datasets
(Manske et al., under review) [20,22,23,24] should greatly enhance
the feasibility for large-scale genotype-based population genetic
studies of the parasite. However, genotyping P. falciparum samples
is challenging owing to features such as limitations in the quantity
of parasite DNA, contamination with human DNA from white
blood cells, and the presence of extensive polymorphism, including
multiple clone infections.
We assessed the utility of the high-throughput Illumina
GoldenGate platform to genotype various preparations of P.
falciparum DNA, and to apply these data to population genetic
studies of the parasite. The Illumina BeadXpress platform, which
primarily uses the Golden Gate SNP genotyping assay but
genotypes lower number of SNPs, has been previously successful
on genotyping 96 SNPs in P. falciparum [25]. However, the ability
of this method to quantify alleles present in multiple clone
infections and the robustness of the assay in the face of human
DNA contamination and limiting starting DNA template had not
been thoroughly explored.
Using a 384-SNP custom-design GoldenGate assay, under strict
criteria for genotype intensity (R.0.1) and concordance between
sample replicates (r2.0.95), 84% (306) of SNPs demonstrated
reliable genotyping performance on both clinical and cultured
samples from a range of geographic locations, including samples
with abundant human contamination and with low quantities of
genomic or whole genome amplified (WGA) DNA.
Multiple clone infections present a challenge to parasite genetic
studies owing to sensitivity of detection of minor frequency
variants and potential ambiguity in haplotype reconstruction.
Accurate haplotype reconstruction is important for certain genetic
metrics which require an understanding of genetic phase, such as
linkage disequilibrium (LD). Patterns of LD underlie methods to
detect signatures of recent positive selection, and candidate loci
underlying traits such as antimalarial drug resistance [26].
Haplotypes can also facilitate the identification of alleles that
although shared between populations, have arisen independently
in different genetic backgrounds (homoplasy), due to the influence
of selection pressures, such as antimalarial drugs . Accurate
haplotype reconstruction is a common problem to most genotyp-
ing platforms. To facilitate genetic analysis in the presence of
multiclonal infections, the common practice is to use the
predominant allele detected at each locus to reconstruct ‘‘infection
haplotypes’’ or to remove multiclonal infections from analysis (the
latter commonly used when performing genotype-phenotype
association studies). Anderson and colleagues observed very similar
LD estimates between these two datasets types in P. falciparum
populations from a range of geographic locations, including highly
diverse and mutliclonal populations from Africa [19]. Single
Table 3. Population genetic characterisation of 143 P. falciparum samples obtained from patients with malaria (short-term and
non-cultured samples) using 306 ‘‘globally reliable’’ SNPs.
Wright’s FST
Expected Heterozygosity
(s.d.)a
Country Thailand Cambodia Kenya Burkina Faso Mali
PNG 0.253 0.243 0.275 0.389 0.391 0.18 (0.19)
Thailand 0.089 0.329 0.463 0.456 0.17 (0.21)
Cambodia 0.326 0.457 0.454 0.18 (0.20)
Kenya 0.088 0.092 0.23 (0.21)
Burkina Faso 0.011 0.24 (0.21)
Mali 0.24 (0.20)
aExpected heterozygosity at each locus was calculated as HE= [n/(n - 1)][2pq]: see Materials and Methods.
doi:10.1371/journal.pone.0020251.t003
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molecule sequencing approaches such as the Illumina Genome
Analyzer platform produce short sequence reads (or read pairs)
which are essentially haplotypes. Particularly with increasing read
lengths, these datasets should provide critical information to
facilitate the imputation of haplotypes from genotyping data.
Indeed, whole genome sequencing platforms provide a useful
approach to identify features such as signatures of selection and
candidate drug resistance or immune evasion loci. With the
capacity to genotype a large set of samples and SNPs in parallel,
using small quantities of parasite DNA (typical in extracts from
filter paper) even in the presence of abundant human DNA,
genotyping platforms such as the GoldenGate assay provide an
important tool to validate these candidate loci in large sample
collections.
In our study, we were able to detect multiclonal infections (as
indicated by the presence of heterozygous genotype calls) in
clinical samples. In addition to identifying whether a sample
carried more than one genetic variant, we were able to describe
the extent of diversity within a sample (i.e. how different the
parasites within a multiple infection are), as defined by the
proportion of heterozygous loci within a sample. Using this
method, we observed higher levels of diversity within the clinical
African samples than in the clinical PNG samples, consistent with
observations from datasets produced on the Illumina Genome
Analyzer platform (Manske et al., under review). Using artificial
mixes of laboratory clones, the 306-SNP assay demonstrated high
specificity (high concordance between replicates) and modest
sensitivity to detect minor frequency variants (generally sensitive at
minor allele frequencies .10%). At this level of sensitivity, using
the 306 validated SNPs on 143 clinical and short-term cultured
samples from across the globe, we observed global patterns of
population genetic diversity and differentiation consistent with
previous reports using data generated on other platforms.
Our study also demonstrated a potential utility of the
GoldenGate assay in assigning the geographic origin to an
infection on the basis of its clustering pattern in PCA and
underlying molecular barcode.
As observed in other studies [20], PCA demonstrated distinct
clustering of samples by continental boundaries, and moderate
clustering by political boundaries. We used this ability to
differentiate samples by geographic origin to identify minimal,
informative subsets of SNPs, or molecular barcodes, to assign the
geographic origin of an infection. A 6-SNP molecular barcode was
sufficient to determine whether a sample was from Thailand or
Cambodia, and a 4-SNP barcode was sufficient to resolve samples
from East and West Africa. Determining whether a sample was
from Mali or Burkina Faso was more ambiguous owing to
apparent substantial gene flow between these populations.
Ongoing whole genome sequencing projects will facilitate
identification of informative SNPs for high-resolution molecular
barcodes. Using appropriate sampling parameters and SNP sets
specific to the population(s) of interest and informed by the latest
Figure 2. Principal Components Analysis plots (x axis represents PC1, and y axis PC2) on the 143 clinical (non-cultured) and short-
termed cultured samples using the 306 ‘‘globally reliable’’ SNPs. Green=Mali Orange=Burkina Faso, Blue= Kenya, Black = Cambodia,
Grey = Thailand, Red =Papua New Guinea. Clear continental differentiation of samples is observed (a). Within continental boundaries, moderate
resolution of Thailand from Cambodia (b), and East Africa from West Africa (c) is observed.
doi:10.1371/journal.pone.0020251.g002
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genome-wide sequencing Plasmodium datasets, greater geographic
positioning resolution, possibly at the village level, is anticipated.
The ability to trace the migratory patterns of parasites has
important implications for malaria control, including potential
utility in drug resistance surveillance studies and identifying
important routes of new infections in populations in the late stages
of malaria elimination and at risk of potential resurgence.
In summary, we discuss the challenges of genotyping in P.
falciparum, and demonstrate high genotyping specificity and
moderate sensitivity even on low quantity (2 ng) DNA templates,
typical of filter paper extracts. In addition to the high sample and
SNP throughput, an important feature of the GoldenGate
platform is its custom-design potential. This feature enables
researchers to select the specific SNPs which best facilitate their
research objective. With ongoing Plasmodium whole-genome
sequencing efforts and the identification of novel candidate disease
and drug resistance loci (Manske et al., under review), researches
will have a large resource of SNPs from which to select optimal
subsets for their specific study design.
Supporting Information
Figure S1 Distribution of theta values (proxy to genotype call) at
306 SNPs in (left to right) the laboratory clone 3D7 and 2 clinical
samples from Burkina Faso and PNG. Values approximating 0
and 1 correspond to homozygous calls while other values represent
heterozygous calls.
(TIF)
Figure S2 Principal Components Analysis plots (x axis repre-
sents PC1, and y axis PC2) using molecular barcodes to
differentiate the 143 samples and assign geographic origins to
the infections. Green=Mali Orange =Burkina Faso, Blue =
Kenya, Black =Cambodia, Grey =Thailand, Red=Papua New
Guinea. Using a 9-SNP molecular barcode, samples can clearly be
assigned continental origins (a) Clear sample assignment to East or
West Africa is possible using a 4-SNP molecular barcode, although
Mali and Burkina Faso cannot be resolved (b). Using a 6-SNP
molecular barcode, samples can be assigned to Thailand or
Cambodia with moderate confidence (c). The highest resolution of
Mali and Burkina Faso is possible with a 13-SNP barcode
(additional SNPs do not improve resolution), but assignment to
either population remains moderately ambiguous (d).
(TIF)
Table S1 Sample details.
(DOCX)
Table S2 Golden Gate custom assay information.
(XLSX)
Table S3 Assessment of assay performance using 319
‘‘reliable’’ SNPs in the presence of human DNA. a Total
250 ng genomic DNA. b Filtration criteria A: SNPs with genotype
concordance between replicates .0.95. c Filtration criteria B:
SNPs with R.0.1 and with genotype concordance between
replicates .0.95. d Mean correlation between replicates.
(DOCX)
Table S4 Assessment of assay performance using 319
‘‘reliable’’ SNPs on whole genome amplified (WGA)
samples. a Filtration criteria A: SNPs with genotype concor-
dance between replicates .0.95. b Filtration criteria B: SNPs with
R.0.1 and with genotype concordance between replicates .0.95.
(DOCX)
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